Drug Trial Radar · NCT04671667
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
188
Planned (sponsor's estimate)
Start
Apr 27, 2021
Primary completion
Jun 30, 2029
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Dec 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Carboplatin is also in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab alone after surgery may work better than the usual approach in shrinking recurrent or primary head and neck squamous cell carcinoma.
Conditions
- Recurrent Head and Neck Squamous Cell Carcinoma
- Recurrent Hypopharyngeal Squamous Cell Carcinoma
- Recurrent Laryngeal Squamous Cell Carcinoma
- Recurrent Oral Cavity Squamous Cell Carcinoma
- Recurrent Oropharyngeal Squamous Cell Carcinoma
Interventions
CarboplatinDrug
Given IV
CisplatinDrug
Given IV
Computed TomographyProcedure
Undergo CT
Intensity-Modulated Radiation TherapyRadiation
Undergo IMRT
Magnetic Resonance ImagingProcedure
Undergo MRI
PembrolizumabBiological
Given IV
Proton Beam Radiation TherapyRadiation
Undergo PBRT
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: From randomization to date of death from any cause, measured at 2 years
- Incidence of adverse eventsTime frame: Up to 5 years from date of registration
Locations
178 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama · Active not recruiting
University of Arkansas for Medical Sciences
Little Rock, Arkansas · Recruiting
Kaiser Permanente-Anaheim
Anaheim, California · Recruiting
Kaiser Permanente-Bellflower
Bellflower, California · Recruiting
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Active not recruiting
UC San Diego Moores Cancer Center
La Jolla, California · Active not recruiting
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California · Recruiting
Kaiser Permanente-Ontario
Ontario, California · Recruiting
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California · Active not recruiting
Sutter Cancer Centers Radiation Oncology Services-Roseville
Roseville, California · Active not recruiting
Sutter Roseville Medical Center
Roseville, California · Active not recruiting
California Protons Cancer Therapy Center
San Diego, California · Active not recruiting
Smilow Cancer Center/Yale-New Haven Hospital
New Haven, Connecticut · Recruiting
Yale University
New Haven, Connecticut · Recruiting
Smilow Cancer Hospital Care Center-Trumbull
Trumbull, Connecticut · Recruiting
Smilow Cancer Hospital Care Center - Waterford
Waterford, Connecticut · Recruiting
MedStar Washington Hospital Center
Washington D.C., District of Columbia · Recruiting
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida · Recruiting
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida · Recruiting
UF Health Cancer Institute - Gainesville
Gainesville, Florida · Active not recruiting
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida · Recruiting
UM Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida · Recruiting
Moffitt Cancer Center-International Plaza
Tampa, Florida · Recruiting
Moffitt Cancer Center - McKinley Campus
Tampa, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Moffitt Cancer Center at Wesley Chapel
Wesley Chapel, Florida · Recruiting
Emory Proton Therapy Center
Atlanta, Georgia · Recruiting
Emory University Hospital Midtown
Atlanta, Georgia · Recruiting
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia · Suspended
Memorial Health University Medical Center
Savannah, Georgia · Suspended
Northwestern University
Chicago, Illinois · Recruiting
John H Stroger Jr Hospital of Cook County
Chicago, Illinois · Recruiting
University of Illinois
Chicago, Illinois · Recruiting
Carle at The Riverfront
Danville, Illinois · Recruiting
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois · Suspended
Decatur Memorial Hospital
Decatur, Illinois · Recruiting
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois · Recruiting
Carle Physician Group-Effingham
Effingham, Illinois · Recruiting
Crossroads Cancer Center
Effingham, Illinois · Recruiting
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois · Recruiting
Showing 40 of 178 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.